3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
3
Gynecologic
2
Gastrointestinal
2
Breast
2
Sarcoma
1
Dermatologic
1
Conditions
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Melanoma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
Specimen Handling
36
Magnetic Resonance Spectroscopy
31
Cyclophosphamide
26
Doxorubicin
23
Biopsy
22
pembrolizumab
21
Temozolomide
21
X-Rays
17
Radiotherapy
17
Radiation
16
Nivolumab
13
atezolizumab
12
Vincristine
12
Phantoms, Imaging
12
Irinotecan
12
Ifosfamide
12
Gemcitabine
12
fludarabine
11
cabozantinib
10
liposomal doxorubicin
8
Surgical Procedures, Operative
8
Ipilimumab
8
Etoposide
8
Bevacizumab
8
Paclitaxel
7
Immunoglobulin G
7
Carboplatin
7
palbociclib
6
olaparib
6
fludarabine phosphate
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Genetic Counseling
×
Sarcoma
×
90 days
×
Clear all
NCT05225428
2026-05-22
VERDI
Dana-Farber Cancer Institute
Phase NA
Recruiting
1,020 enrolled